Compared to the rapid development of immunotherapies in solid tumors, PD1/PD-L1 antibodies showed limited clinical activity in AML (Zhang et al., 2009; Zhou et al., 2010; Zhou et al., 2011), we still have a long way to develop immunotherapies for myeloid leukemia. This evidence concerns the gene CD274 and myeloid leukemia.